Biopharma Deploy Trump’s Tax Windfall to Buy Back Billions in Stock

“Large-cap biopharmaceutical companies took advantage of repatriation of overseas profits and lower corporate tax rates to push share repurchases to the highest level in at least 10 years.”   More …

Leave a Reply

Your email address will not be published. Required fields are marked *